Knowledge on the guideline-recommended use of antiplatelet and anticoagulant therapy during dental extractions : a contemporary survey among Polish dentists by Tokarek, Tomasz et al.
KARDIOLOGIA POLSKA 2020; 78 (11)1122
is a growing population of patients with clinical 
indications for anticoagulant therapy with vita‑
min K antagonists (VKAs) or non ‑VKA oral anti‑
coagulants (NOACs).2‑4 Most dental procedures 
are associated with a low risk of bleeding and 
self ‑limited blood loss that might be managed 
with local hemostatic agents. However, the use 
IntroductIon The number of dental pa‑
tients requiring periodic or lifelong treatment 
with antiplatelet or anticoagulant agents has 
been increasing worldwide.1 Dual antiplatelet 
therapy (DAPT) with P2Y12 inhibitors in addition 
to aspirin is required in all patients after percu‑
taneous coronary intervention. Moreover, there 
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AbstrAct
Background The number of dental patients requiring periodic or lifelong antiplatelet or anticoagulant 
therapy is constantly growing.
aims We aimed to determine the level of knowledge on antiplatelet and anticoagulant therapy among 
Polish dentists.
methods A self ‑designed online questionnaire was distributed among dentists to evaluate their 
knowledge on the use of antiplatelet and anticoagulant drugs in clinical dental practice.
results The study included 352 dentists. Patients requiring vitamin K antagonists were referred for a 
cardiac consultation by 64.52%, 57.29%, and 58.55% of dentists with <5, 5–15, and >15 years of experience, 
respectively (P = 0.003). A similar trend was observed for non–vitamin K antagonist oral anticoagulants 
among nonsurgical dentists. However, an equal percentage of surgical dentists (39.7%) performed 
extraction with and without consultation, and they were more likely to perform extraction without 
consultation than nonsurgical dentists (39.7% vs 27.8%; P = 0.01). Most surgical and nonsurgical dentists 
preferred to consult a cardiologist about dual antiplatelet therapy before an invasive procedure (56.9% 
and 73.81%, respectively; P = 0.03). Extractions in patients on aspirin were accepted by 75.81%, 70.83%, 
and 49.34% of dentists with <5, 5–15, and >15 years of experience, respectively (P = 0.004), and by 79.31% 
of surgical and 57.14% of nonsurgical dentists (P = 0.003).
conclusions Knowledge on antiplatelet and anticoagulant therapy in patients undergoing dental 
procedures is unsatisfactory among Polish dentists. Both therapies were discontinued before extractions 
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regarding the sociodemographic and clinical 
profile of respondents as well as their clini‑
cal decisions regarding DAPT and anticoag‑
ulant treatment in patients requiring dental 
extractions. There was no time limit for any of 
the questions. The survey was open for 1 month, 
and multiple attempts were made to promote 
it among dentists. A total of 352 dentists re‑
sponded to the survey and were included in 
the study group. Respondents included surgi‑
cal specialists, defined as dental surgeons and 
maxillofacial surgeons, as well as nonsurgical 
dentists. Experience was defined as years of 
clinical practice (<5, 5–15, and >15 years).
ethical concerns The study protocol was ap‑
proved by the Bioethics Committee of Poznan 
University of Medical Sciences. The study was 
conducted in accordance with ethical principles 
for clinical research based on the Declaration of 
Helsinki with later amendments.
statistical analysis Standard descriptive sta‑
tistical calculations were used. The normal dis‑
tribution of data was evaluated with the Shap‑
iro–Wilk test. Categorical variables were pre‑
sented as numbers and percentages. The χ2 test 
for categorical variables was used for direct com‑
parisons between groups. The level of statistical 
significance was set at a P value of 0.05 or lower. 
All analyses were conducted with the STATISTI‑
CA version 13 software (StatSoft, Inc., Kraków, 
Poland).
results Of the 352 respondents included in 
the study, 182 (51.7%) had over 15 years of ex‑
perience in dentistry. A minority of respondents 
had surgical specialty, but nearly half of the par‑
ticipants were specialists in other specialties. De‑
tailed distribution of respondents according to 
specialty and experience is presented in FIgUre 1. 
Regardless of experience, most respondents were 
more likely to consult a cardiologist before den‑
tal extraction in patients requiring VKA treat‑
ment (TAble 1). Similar results were noted for surgi‑
cal specialists regarding patients on NOAC thera‑
py. However, an equal percentage of surgical den‑
tists would perform extraction with and with‑
out consultation with a cardiologist (TAble 1). On 
the other hand, dentists without surgical spe‑
cialty preferred to consult a cardiologist before 
invasive procedures in patients receiving NOAC 
therapy. Regardless of the specialty, most den‑
tists did not require the international normal‑
ized ratio (INR) value before dental extraction 
in patients on NOACs (TAble 2). Surgical special‑
ists accepted the INR value measured 24 hours 
before extraction, while most dentists without 
surgical specialty considered the results up to 
48 hours before the procedure as reliable. These 
results show that many dentists made clinical 
of anticoagulants is linked with a higher risk of 
bleeding complications, especially when used in 
combination with common nonsteroidal anti‑
‑inflammatory drugs.5‑10 Yet, discontinuation 
of these drugs might result in cardiovascular 
complications such as thrombosis or ischemic 
stroke.11,12 Therefore, it is crucial that dentists 
have sufficient knowledge on the management of 
these patients to avoid such complications in dai‑
ly dental practice. Continuation of DAPT is asso‑
ciated with a low risk of bleeding complications 
after dental extractions.12 In addition, single an‑
tiplatelet therapy with aspirin seems to have no 
impact on bleeding risk, thus antiplatelet treat‑
ment should not be interrupted.12,13 In patients 
with high bleeding risk, both VKAs and NOACs 
should be discontinued. On the other hand, pa‑
tients at increased risk of thrombosis might re‑
quire a consultation with a cardiologist.12 In gen‑
eral, dental extractions can be safely performed 
without stopping the anticoagulant treatment 
by using hemostatic agents as prophylaxis or by 
omitting only one morning dose of a NOAC.14,15 
Despite the widespread use of DAPT and anti‑
coagulants, there are scarce data on the adher‑
ence of dentists to the current standard of care.1,16 
Therefore, we conducted this study to determine 
the level of knowledge on antiplatelet and antico‑
agulant therapy among Polish dentists as well as 
the extent to which they adhere to current guide‑
lines. Moreover, by identifying the possible ar‑
eas that need improvement, we aimed to raise 
the awareness of the problem among healthcare 
providers in Poland.
Methods A self ‑designed online question‑
naire was administered to all registered mem‑
bers of the Polish Dental Association (approx‑
imately 3000 members) via email to evaluate 
their level of knowledge on the use of antiplate‑
let and anticoagulant treatment in clinical den‑
tal practice (Supplementary material). Ques‑
tions were modeled according to the current 
guidelines of the European Society of Cardi‑
ology.3,17 The questionnaire included questions 
whAt’s new?
With increased life expectancy, there has been an exponential growth in 
the population of dental patients requiring periodic or lifelong treatment 
with antiplatelet or anticoagulant drugs. Despite the widespread use of dual 
antiplatelet therapy and anticoagulants, data on the adherence of dentists 
to current recommendations are scarce. Our study suggests that Polish 
dentists have insufficient knowledge on antiplatelet and anticoagulant 
treatment of patients undergoing invasive dental procedures. Treatment with 
antiplatelets and oral anticoagulants was interrupted before dental extractions 
more often than recommended in the guidelines. On the other hand, dental 
extractions were common in patients taking aspirin. There is a continuous 
need for up ‑to ‑date knowledge on antiplatelet or anticoagulant therapy 
among Polish dentists.
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decisions on the basis of INR values that were 
invalid or outdated. Furthermore, many respon‑
dents unnecessarily required the INR value be‑
fore invasive procedures in patients on NOACs 
(TAble 3). No differences in the level of knowledge 
on anticoagulant therapy were noted between 
dentists during training and specialists. More‑
over, experience had no impact on routine INR 
testing before the procedure (TAbles 2 and 3). Sim‑
ilar results were observed regarding patients on 
DAPT. Both surgical and nonsurgical dentists 
were more likely to refer patients to a cardiolo‑
gist prior to invasive procedures (TAble 4). Howev‑
er, a minority of respondents considered dental 
extraction to be safe in patients on DAPT. Den‑
tal extraction in patients taking aspirin was 
considered safe regardless of experience. Both 
surgical and nonsurgical specialists were likely 
to perform tooth extraction in patients on as‑
pirin (TAble 5).
dIscussIon Our study demonstrated that 
Polish dentists more often discontinue antiplate‑
let or oral anticoagulant therapy in their patients 
prior to dental extractions than it is recommend‑
ed in the guidelines. Moreover, we noted major 
differences among dentists in the use of anti‑
platelet and anticoagulant therapy depending 
on specialty and experience defined as years of 
Table 1 Dental extractions in patients on anticoagulant therapy
Respondents Yes Yes, but with 
the omission of 
the morning drug dose
No, I would 
consult 
a cardiologist
No, I would refer to 
another dentist
P value
Dental extraction on VKAs (warfarin, acenocoumarol) with INR in the therapeutic range
Years of dental practice <5 19 (30.7) 2 (3.2) 40 (64.5) 1 (1.6) 0.003
5–15 36 (37.5) 2 (2.1) 55 (57.3) 3 (3.1)
>15 26 (17.1) 20 (13.2) 89 (58.6) 17 (11.2)
Any dental specialty Yes 35 (25.7) 15 (11) 76 (55.9) 10 (7.4) 0.3
No 46 (26.4) 9 (5.2) 108 (62.1) 11 (6.3)
Surgical specialty Yes 18 (31) 6 (10.3) 34 (58.6) 0 0.1
No 63 (25) 18 (7.1) 150 (59.5) 21 (8.3)
Dental extraction on NOACs (dabigatran, rivaroxaban, apixaban)
Years of dental practice <5 22 (35.5) 5 (8.1) 32 (51.6) 3 (4.9) 0.3
5–15 31(32.3) 13 (13.5) 47 (48.9) 5 (5.2)
>15 40 (26.3) 26 (17.1) 71 (46.7) 15 (9.9)
Any dental specialty Yes 42 (30.9) 23 (16.9) 61 (44.9) 10 (7.4) 0.6
No 51 (29.3) 21 (12.1) 89 (51.2) 13 (7.5)
Surgical specialty Yes 23 (39.7) 12 (20.7) 23 (39.7) 0 0.01
No 70 (27.8) 32 (12.7) 127 (50.4) 23 (9.1)
Data are presented as the number (percentage) of respondents.
Abbreviations: INR, international normalized ratio; NOAC, non–vitamin K antagonist oral anticoagulant; VKA, vitamin K antagonist
Figure 1 Distribution of the study group according to: a – dental specialty; B – experience 
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extraction with and without consultation with 
a cardiologist. Regardless of the specialty, most 
dentists preferred to consult a cardiologist be‑
fore an invasive procedure in patients on DAPT. 
In contrast, dental extractions on aspirin treat‑
ment were considered safe by most practitioners, 
clinical practice. Patients requiring treatment 
with VKAs were more often referred by den‑
tists to a cardiologist, regardless of experience. 
A similar trend for NOAC therapy was observed 
among nonsurgical dentists. However, an equal 
percentage of surgical dentists would perform 
Table 2 Knowledge on the importance of international normalized ratio measurement before dental extrac­
tion in patients on oral anticoagulant therapy
Respondents Do you order the INR test before dental extraction in 
a patient receiving a NOAC?
P value
Yes No
Years of dental practice <5 28 (45.2) 34 (54.8) 0.5
5–15 36 (37.5) 60 (62.5)
>15 68 (44.7) 84 (55.3)
Any dental specialty Yes 54 (39.7) 82 (60.3) 0.4
No 78 (44.8) 96 (55.2)
Surgical specialty Yes 16 (27.6) 42 (72.4) 0.01
No 116 (46) 136 (53.9)
Data are presented as the number (percentage) of respondents.
Abbreviations: see TAble 1
Table 3 Time range for reliability of the international normalized ratio value before extraction in patients 
receiving vitamin K antagonists
Respondents Till 48 hours Till 24 hours Till 5 days Till 7 days P value
Years of dental practice <5 25 (40.3) 29 (46.8) 5 (8.1) 3 (4.8) 0.4
5–15 41 (42.7) 41 (42.7) 7 (7.3) 7 (7.3)
>15 52 (34.2) 63 (41.5) 23 (15.1) 14 (9.2)
Any dental specialty Yes 51 (37.5) 61 (44.9) 16 (11.8) 8 (5.9) 0.7
No 67 (38.5) 72 (41.4) 19 (10.9) 16 (9.2)
Surgical specialty Yes 16 (27.6) 35 (60.3) 4 (6.9) 3 (0.9) 0.03
No 102 (40.5) 98 (38.9) 31 (12.3) 21 (8.3)
Data are presented as the number (percentage) of respondents.
Table 4 Dental extractions in patients on dual antiplatelet therapy (aspirin and clopidogrel or prasugrel or 
ticagrelor)
Respondents Yes Yes, but with 
cessation of one 
antiplatelet drug
Yes, but with 
cessation of both 
antiplatelet drugs







<5 14 (22.6) 3 (4.8) 1 (1.6) 44 (70.9) 0.2
5–15 16 (16.7) 8 (8.3) 6 (6.3) 66 (68.8)
>15 17 (11.2) 16 (10.5) 10 (6.6) 109 (71.7)
Any dental 
specialty
Yes 19 (13.9) 13 (9.6) 10 (7.4) 94 (69.1) 0.6
No 28 (16.1) 14 (8.1) 7 (4) 125 (71.8)
Surgical 
specialty
Yes 15 (25.9) 5 (8.6) 5 (8.6) 33 (56.9) 0.03
No 32 (12.7) 22 (8.7) 12 (4.8) 186 (73.8)
Data are presented as the number (percentage) of respondents.
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relatively better than in other countries. There‑
fore, it is important to allow time for the imple‑
mentation of guidelines and provide education‑
al courses for dentists in primary care. Knowl‑
edge on NOAC treatment was also shown to 
improve, with up to 87% of practitioners re‑
porting familiarity with these drugs. It was re‑
vealed that 62.9% of respondents did not mod‑
ify the treatment before invasive oral proce‑
dures, 70.8% did not evaluate coagulation pa‑
rameters, and only 13.9% measured the INR.25 
The level of knowledge differed among Polish 
dentists depending on the type of treatment, 
although major gaps were revealed both for an‑
tiplatelets and anticoagulants. Many dentists 
may not be familiar with the specific charac‑
teristics of these drugs, which greatly impairs 
the decision ‑making process.
Several randomized trials demonstrated that 
discontinuation of DAPT increases the risk of 
stent thrombosis, which may occur either as 
an early or late complication.2,26,27 Stent throm‑
bus is associated with a high incidence of myocar‑
dial infarction and a short ‑term mortality rate of 
up to 50% to 70%.2,17 Moreover, NOACs are crucial 
for stroke prevention in patients with atrial fibril‑
lation.18‑21 Withdrawal of anticoagulant therapy 
could lead to ischemic stroke, potentially resulting 
in disability or death. Therefore, continuation of 
both DAPT and NOACs is crucial for the preven‑
tion of major adverse cardiac events,26‑29 although 
it is associated with the risk of bleeding complica‑
tions. The bleeding risk is possibly the most im‑
portant factor to be taken into account by den‑
tists when considering discontinuation of one or 
both therapies. Careful patient selection is essen‑
tial for preventing complications. Basic classifi‑
cation of dental procedures into those with low 
and high bleeding risk might be helpful.26‑29 An in‑
dividual approach to patients is necessary, with 
the assessment not only of local bleeding risk re‑
lated to a dental procedure but also of thrombot‑
ic and bleeding risk related to cardiovascular dis‑
ease.30 Most dental interventions might be safely 
performed without modification of antiplatelet 
regardless of the specialty and experience. A re‑
ferral to a cardiologist might sometimes be ben‑
eficial (eg, in cases of tooth extraction with‑
in 2–4 weeks after percutaneous coronary in‑
tervention); therefore, its value should not be 
underestimated.
Our major findings are in line with most con‑
temporary studies. Recently, Ringel and Maas18 
reported that tooth extractions in patients on 
aspirin and VKAs were performed by 77.4% and 
27.6% of dentists, respectively. Furthermore, 
29.5% of dentists accepted the INR values above 
and below the therapeutic range (≤1.5 or ≥3.5). 
Over 90% of respondents accepted INR values 
that were too old to be clinically reliable.18 An‑
other study confirmed that dentists had limited 
knowledge on antiplatelet drugs and the conse‑
quences of therapy discontinuation.19,20 A recent 
survey demonstrated that 15.9% of respondents 
systematically discontinued VKAs before inva‑
sive oral procedures, 25.3% administered hepa‑
rin instead, and only 16.5% did not discontinue 
VKA therapy.21 Only 11.2% of practitioners were 
familiar with the guidelines, mostly young den‑
tists and women. An Irish study revealed that 
25% of respondents did not measure the INR 
before dental extractions in patients receiving 
VKAs.22 Furthermore, in a survey among Danish 
dentists, 50% of participants were not familiar 
with the INR test.23 A study conducted in India 
showed that only 7.1% of dentists from univer‑
sity centers were familiar with NOACs.24 Finally, 
a recent study, conducted 11 years after the first 
French guidelines on anticoagulant therapy in 
oral surgery, showed that 95% of practitioners 
performed invasive procedures in patients treat‑
ed with VKAs (mostly low risk of bleeding).25 
Participants showed a high level of knowledge 
about VKA treatment, INR monitoring, and lo‑
cal hemostatic techniques.25 A substantial im‑
provement in the level of knowledge was noted 
in comparison with a previous study.21,25
Although Polish dentists showed suboptimal 
knowledge about the importance of INR moni‑
toring in patients on VKAs and NOACs, it was 
Table 5 Dental extractions in patients on aspirin
Respondents Yes Yes, but with 
cessation of aspirin
No, I would consult 
a cardiologist
P value
Years of dental 
practice
<5 47 (75.8) 9 (14.5) 6 (9.7) 0.004
5–15 68 (70.8) 18 (18.8) 10 (10.4)
>15 75 (49.3) 58 (38.2) 19 (12.5)
Any dental 
specialty
Yes 82 (60.3) 40 (29.4) 14 (10.3) 0.7
No 108 (62.1) 45 (25.9) 21 (12.1)
Surgical specialty Yes 46 (79.3) 11 (18.9) 1 (1.7) 0.003
No 144 (57.1) 74 (29.4) 34 (13.5)
Data are presented as the number (percentage) of respondents.
O R I G I N A L  A R T I C L E  Antiplatelet and anticoagulant therapy during dental extractions 1127
and share them with others, provided the original work is properly cited, not 
changed in any way, distributed under the same license, and used for noncom‑
mercial purposes only. For commercial use, please contact the journal office 
at kardiologiapolska@ptkardio.pl.
how to cite Tokarek T, Homaj M, Zabojszcz M, et al. Knowledge on 
the guideline ‑recommended use of antiplatelet and anticoagulant therapy dur‑
ing dental extractions: a contemporary survey among Polish dentists. Kardiol Pol. 
2020; 78: 1122‑1128. doi:10.33963/KP.15588
references
1 Population Division. Department of economic and social Affairs. United Na‑
tions. revision of World Population Prospects. https://esa.un.org/unpd/wpp/. Ac‑
cessed April 3, 2020.
2 Neumann FJ, sousa ‑Uva M, Ahlsson A, et al; esC scientific Document group. 
2018 esC/eACTs guidelines on myocardial revascularization. eur Heart J. 2019; 40: 
87‑165.
3 Kirchof P, benussi s, Kotecha D, et al. 2016 esC guidelines for the manage‑
ment of atrial fibrillation developed in collaboration with eACTs. eur Heart J. 2016; 
37: 2893‑2962.
4 Heidbuchel H, Verhamme P, Alings M, et al. european Heart rhythm Associ‑
ation Practical guide on the use of new oral anticoagulants in patients with non‑
‑valvular atrial fibrillation. europace. 2013; 15: 625‑651.
5 Chee Yl, Crawford JC, Watson Hg, et al. guidelines on the assessment of 
bleeding risk prior to surgery or invasive procedures. british Committee for stan‑
dards in Haematology. br J Haematol. 2008; 140: 496‑504.
6 Fleisher lA, Fleischmann Ke, Auerbach AD, et al. 2014 ACC/AHA guideline on 
perioperative cardiovascular evaluation and management of patients undergo‑
ing noncardiac surgery: a report of the American College of Cardiology/Ameri‑
can Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2014; 
64: 77‑137.
7 siller ‑Matula JM, Petre A, Delle ‑Karth g, et al. Impact of preoperative use of 
P2Y12 receptor inhibitors on clinical outcomes in cardiac and non ‑cardiac surgery: 
a systematic review and meta ‑analysis. eur Heart J Acute Cardiovasc Care. 2017; 
6: 753‑770.
8 Cannon PD, Dharmar VT. Minor oral surgical procedures in patients on oral an‑
ticoagulants ‑ a controlled study. Aust Dent J. 2003; 48: 115‑118.
9 Kämmerer PW, Frerich b, liese J, et al. Oral surgery during therapy with anti‑
coagulants ‑ a systematic review. Clin Oral Investig. 2015; 19: 171‑180.
10 shi Q, Xu J, Zhang T, et al. Post ‑operative bleeding risk in dental surgery for 
patients on oral anticoagulant therapy: a meta ‑analysis of observational studies. 
Front Pharmacol. 2017; 8: 58.
11 burger W, Chemnitius JM, Kneissl gD, et al. low ‑dose aspirin for secondary 
cardiovascular prevention ‑ cardiovascular risks after its perioperative withdraw‑
al ‑versus bleeding risks with its continuation – review and meta ‑analysis. J Inter‑
nal Med. 2005; 257: 399‑414.
12 Pruszczyk P, Ciurzyński M, Opolski g, et al. Dental cardio common position 
for dealing anticoagulation in patients undergoing dental procedures [in Polish]. 
Kardiol Pol. 2016; 74: 87‑98.
13 Zabojszcz M, Malinowski KP, Janion ‑sadowska A, et al. safety of dental extrac‑
tions in patients on dual antiplatelet therapy ‑ a meta ‑analysis. Postepy Kardiol In‑
terwencyjnej. 2019; 15: 68‑73.
14 Mauprivez C, Khonsari rH, razouk O, et al. Management of dental extraction 
in patients undergoing anticoagulant oral direct treatment: a pilot study. Oral surg 
Oral Med Oral Pathol Oral radiol. 2016; 122: 146‑155.
15 Miclotte I, Vanhaverbeke M, Agbaje JO, et al. Pragmatic approach to manage 
new oral anticoagulants in patients undergoing dental extractions: a prospective 
case ‑control study. Clin Oral Investig. 2017; 21: 2183‑2188.
16 Dudek D, siudak Z, grygier M, et al. Interventional cardiology procedures in 
Poland in 2018. summary report of the Association of Cardiovascular Interventions 
of the Polish Cardiac society (AIsN PTK) and Jagiellonian University Medical Col‑
lege. Postepy Kardiol Interwencyjnej. 2019; 15: 391‑393.
17 Valgimigli M, bueno H, byrne rA, et al. 2017 esC focused update on dual an‑
tiplatelet therapy in coronary artery disease developed in collaboration with eACTs. 
eur Heart J. 2018; 39: 213‑260.
18 ringel r, Maas r. Dental procedures in patients treated with antiplatelet or 
oral anticoagulation therapy ‑ an anonymous survey. gerodontology. 2016; 33: 
447‑452.
19 Can MM, biteker M, babur g, et al. Knowledge, attitude and perception 
of antiplatelet therapy among dentists in Central eastern Turkey. World J Cardi‑
ol. 2012; 4: 226‑230.
20 lozano I, Martín D, Torres F, et al. Knowledge of coronary stents, thrombo‑
sis and dual antiplatelet therapy among spanish dentists. rev esp Cardiol. 2009; 
62: 153‑157.
21 Massot M, Clipet F, Alno N, et al. Étude épidémiologique sur les extractions 
dentaires chez les patients sous AVK en Ille ‑et ‑Vilaine. Med buccale Chir buccale 
Hors série. 2009; 15: 29‑37.
22 Murphy J, Twohig e, Mcwilliams sr. Dentists’ approach to patients on anti‑
‑platelet agents and warfarin: a survey of practice. J Ir Dent Assoc. 2010; 56: 28‑31.
or anticoagulant therapy. In our study, surgical 
dentists were more likely to make such decisions 
on their own than those without surgical special‑
ty. However, adherence to the current standards 
of care among Polish dentists is still low, and 
the knowledge on the management of patients 
treated with antiplatelet or anticoagulant drugs 
remains suboptimal. As the number of patients 
requiring such treatment is expected to grow due 
to increased life expectancy, it is crucial to im‑
prove current knowledge and awareness among 
practicing dentists.
limitations Our results should be considered 
in light of several limitations. Most important‑
ly, the size of the study group was relatively low. 
Even though the online questionnaire was easy 
to use, quick to complete, and was actively pro‑
moted among the members of the Polish Den‑
tal Association, the response rate was only 12%. 
It is possible that dentists who did not complete 
the survey have poorer knowledge on the sub‑
ject, which may have biased our results. There‑
fore, our study may not adequately reflect the ac‑
tual level of knowledge among Polish dentists. 
However, the sample was similar to that in pre‑
vious studies from other countries, such as Ger‑
many or Spain. Moreover, there is a limited num‑
ber of patients treated with DAPT and VKAs or 
NOACs per each dentist. We did not evaluate 
dentists’ experience by the number of patients 
treated (number of extractions) or treatment 
outcomes. The definition of experience adopted 
in our study as years of clinical practice might 
not fully reflect the actual clinical experience.
conclusions The management of patients re‑
ceiving antiplatelet and anticoagulant drugs 
and undergoing dental procedures seems to be 
unsatisfactory in Poland. Polish dentists show 
suboptimal adherence to guidelines, and both 
therapies were discontinued prior to dental ex‑
tractions more frequently than recommend‑
ed. On the other hand, dental extractions were 
common in patients on aspirin. Ongoing efforts 
should be made to propagate up ‑to ‑date knowl‑
edge on antiplatelet and anticoagulant thera‑
py among Polish dentists in the form of train‑
ing courses or webinars. Multidisciplinary task 
force groups including both cardiologists and 
dentists should be created to establish an agen‑
da and oversee the implementation of measures 
as part of quality control.
supplementary material
supplementary material is available at www.mp.pl/kardiologiapolska.
article information
conflict of interest None declared.
open access This is an Open Access article distributed under the terms 
of the Creative Commons Attribution ‑NonCommercial ‑NoDerivatives 4.0 Inter‑
national license (CC bY ‑NC ‑ND 4.0), allowing third parties to download articles 
KARDIOLOGIA POLSKA 2020; 78 (11)1128
23 Van Diermen De, bruers JJ, Hoogstraten J, et al. Treating dental patients who 
use oral antithrombotic medication: a survey of dentists in the Netherlands. J Am 
Dent Assoc. 2011; 142: 1376‑1382.
24 Chinnaswami r, bagadia rK, Mohan A, et al. Dentists’ knowledge, attitude 
and practice in treating patients taking oral antithrombotic medications – a survey. 
J Clin Diagn res. 2017; 11: 88‑91.
25 radoï l, Hajage D, giboin C, et al. Perioperative management of oral antico‑
agulated patients undergoing an oral, implant, or periodontal procedure: a survey 
of practices of members of two dental scientific societies, the PrADICO study. Clin 
Oral Investig. 2019; 23: 4311‑4323.
26 Furie Kl, goldstein lb, Albers gW, et al. Oral antithrombotic agents for 
the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for 
healthcare professionals from the American Heart Association/American stroke 
Association. stroke. 2012; 43: 3442‑3453.
27 Fortier K, shroff D, reebye UN. review: an overview and analysis of novel 
oral anticoagulants and their dental implications. gerodontology 2018; 35: 78‑86.
28 Ciurus T, sobczak s, Cichocka ‑radwan A, et al. New oral anticoagulants – 
a practical guide. Kardiochir Torakochirurgia Pol. 2015; 12: 111‑118.
29 Pruszczyk P, Tomaszuk ‑Kazberuk A, słowik A, et al. Management of bleeding 
or urgent interventions in patients treated with direct oral anticoagulants: 2017 
recommendations for Poland. Pol Arch Intern Med. 2017; 127: 343‑351.
30 Douketis JD, Darvish ‑Kazem s, spencer N, Tafur A. Perioperative manage‑
ment of patients who are receiving antiplatelet therapy: a case ‑based, evidence‑
‑informed approach. Pol Arch Intern Med. 2018; 128: 771‑778.
